Chemoradiation Induces A Proangiogenic and Protumor Circulating Cytokine Profile

S. L. Shiao,P. Noe,Y. Kubota,W. Yang,N. N. Nissen,A. E. Hendifar,R. Tuli

DOI: https://doi.org/10.1016/j.ijrobp.2015.07.1009

2015-01-01

Abstract:Locally advanced pancreatic cancer has a dismal prognosis with current treatment modalities. Given this poor outcome, we initiated a Phase I trial of concurrent veliparib, gemcitabine and fractionated radiation therapy for patients with locally advanced pancreatic disease. With the recent recognition of the important role played by the immune system in the response to radiation and other cytotoxic therapy, we sought to identify immune-related biomarkers as a part of this study that correlated with treatment response and/or toxicity. Blood samples were collected from 11 patients enrolled on the trial before the initiation of treatment, every week during radiation and then at 1, 3 and 6 months following radiation. The serum from each time point was then analyzed using MesoScale V-Plex electrochemiluminescent array to determine the level of 40 different analytes from four categories: angiogenesis, cytokines, vascular injury and chemokines. Differences between baseline levels and subsequent time points were analyzed using two-way ANOVA. All 11 patients studied received the entire course of veliparib, gemcitabine and radiation (RT). We found that during RT that levels of inflammatory markers C-reactive protein (CRP) and serum amyloid A (SAA), interleukin (IL)-6 increase significantly by 4 weeks of treatment. This rise in inflammatory markers is also accompanied by increases in cytokines including IL-5 and IL-15 which affect the polarization and homeostasis of immune cells, particularly T cells. We also find that markers of angiogenesis Phosphatidylinositol-glycan biosynthesis class F protein (PIGF) and vascular endothelial growth factor (VEGF)-D are also elevated in the serum in a parallel pattern to the inflammatory markers and cytokines. All patients demonstrated a similar cytokine pattern suggesting a common pathway of inflammation in response to combined therapy. The results from this study indicate that there is a common and stereotyped inflammatory response to chemoradiation. From this we hypothesize, that chemoradiation induces an inflammatory program that results in a pro-angiogenic through PIGF and VEGF and pro-tumor via IL-5 tumor microenvironment. This data further suggests that there may be inflammation-related biomarkers of response to therapy and identifies potential targets for immunomodulating agents.